The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the disease successfully, new therapeutic strategies are urgently needed. One of these strategies can be the use of neurokinin-1 receptor (NK-1R) antagonists (e.g., aprepitant), because the substance P (SP)/NK-1R syst...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Miguel Muñoz, Rafael Coveñas
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI AG 2020-06-01
Sarja:Journal of Clinical Medicine
Aiheet:
substance P
NK-1R
AML
aprepitant
anti-leukemic
apoptosis
Linkit:https://www.mdpi.com/2077-0383/9/6/1659
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia